EIF-4E Expression and Its Role in Malignancies and Metastases
Overview
Oncology
Authors
Affiliations
The contribution of the mRNA cap-binding protein, eIF-4E, to malignant transformation and progression has been illuminated over the past decade. eIF-4E overexpression has been demonstrated in human tumors of the breast, head and neck, colon, prostate, bladder, cervix and lung, and has been related to disease progression. Overexpression of eIF-4E in experimental models dramatically alters cellular morphology, enhances proliferation and induces cellular transformation, tumorigenesis and metastasis. Conversely, blocking eIF-4E function by expression of antisense RNA, or overexpression of the inhibitory eIF-4E binding proteins (4E-BPs), suppresses cellular transformation, tumor growth, tumor invasiveness and metastasis. Although eIF-4E regulates the recruitment of mRNA to ribosomes, and thereby globally regulates cap-dependent protein synthesis, eIF-4E contributes to malignancy by selectively enabling the translation of a limited pool of mRNAs--those that generally encode key proteins involved in cellular growth, angiogenesis, survival and malignancy (e.g. cyclin D1, c-myc, vascular endothelial growth factor, matrix metalloprotease 9). A deeper understanding of the role of eIF-4E in regulating the translation of the diverse gene products involved in all aspects of malignancy will improve the capacity to exploit eIF-4E as a therapeutic target and as a marker for human cancer progression.
Sortase-Mediated Fluorescent Labeling of eIF4E for Investigating Translation Initiation Mechanisms.
Pi J, Joseph S Biochemistry. 2025; 64(5):1099-1108.
PMID: 39968718 PMC: 11887568. DOI: 10.1021/acs.biochem.4c00851.
Lum M, Jonas K, Parmar S, Black A, OConnor C, Dobersch S J Clin Invest. 2025; 135(4).
PMID: 39869680 PMC: 11827888. DOI: 10.1172/JCI176093.
Okano Y, Yamauchi T, Fukuzaki R, Tsuruta A, Yoshida Y, Tsurudome Y J Biol Chem. 2024; 300(11):107890.
PMID: 39413876 PMC: 11650723. DOI: 10.1016/j.jbc.2024.107890.
Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets.
Sehrawat U Int J Mol Sci. 2024; 25(19).
PMID: 39409166 PMC: 11477148. DOI: 10.3390/ijms251910835.
Bordone R, Ivy D, DAmico R, Barba M, Gaggianesi M, Di Pastena F Oncogene. 2024; 43(46):3349-3365.
PMID: 39306615 DOI: 10.1038/s41388-024-03170-6.